NCT02183298已完成1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.5 mg to 10 mg) of BI 1356 BS as Formulation for Intravenous Administration in Healthy Male Volunteers. A Randomised, Single-blind, Placebo-controlled Trial, Including a Crossover Intra-subject Bioavailability Comparison of 5 mg BI 1356 BS iv Solution and 10 mg BI 1356 BS as Tablet.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- Number of patients with abnormal findings in physical examination
研究概览
简要总结
Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 as formulation for intravenous administration
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests
- •Age ≥18 and Age ≤50 years
- •BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- •A history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- •Exclusion criteria specific for this study:
- •Veins unsuitable for infusion
- •PR interval >220 ms or QRS interval >120 ms
研究组 & 干预措施
BI 1356 BS - single rising dose
Experimental
干预措施: BI 1356 BS - intravenous (Drug)
BI 1356 BS - single rising dose
Experimental
干预措施: BI 1356 BS - Tablet (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients with abnormal findings in physical examination
时间窗: Screening, up to 14 days following drug administration
Number of patients with adverse events
时间窗: up to 35 days
Assessment of tolerability by investigator on a 4-point scale
时间窗: up to 14 days following drug administration
Number of patients with abnormal changes in laboratory parameters
时间窗: Screening, up to 14 days following drug administration
Number of patients with clinically changes in vital signs (blood pressure [BP], pulse rate [PR])
时间窗: Screening, up to 14 days following drug administration
Number of patients with abnormal findings in 12-lead ECG (electrocardiogram)
时间窗: Screening, up to 14 days following drug administration
次要结局
- Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)(predose, up to 120 h following drug administration)
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(predose, up to 192 h following drug administration)
- tmax (time from dosing to maximum measured concentration)(predose, up to 192 h following drug administration)
- %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)(predose, up to 192 h following drug administration)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)(predose, up to 192 h following drug administration)
- CL/ CL/F (total clearance of the analyte in plasma after iv/oral administration)(predose, up to 192 h following drug administration)
- Vz/ Vz/F (apparent volume of distribution during the terminal phase λz following an iv/oral dose)(predose, up to 192 h following drug administration)
- λz (terminal rate constant in plasma)(predose, up to 192 h following drug administration)
- MRT/ MRTpo (mean residence time of the analyte in the body after iv/oral administration)(predose, up to 192 h following drug administration)
- Cmax (maximum measured concentration of the analyte in plasma)(predose, up to 192 h following drug administration)
- Vss (apparent volume of distribution at steady state following intravascular administration)(predose, up to 192 h following drug administration)
- CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)(predose, up to 120 h following drug administration)
- t1/2 (terminal half-life of the analyte in plasma)(predose, up to 192 h following drug administration)
- fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)(predose, up to 120 h following drug administration)
- Changes of Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma(up to 192 h following drug administration)
研究者
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02183415Boehringer Ingelheim77
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male VolunteersHealthyNCT02183311Boehringer Ingelheim56
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02183350Boehringer Ingelheim47
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male SubjectsHealthyNCT02211989Boehringer Ingelheim53
终止
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02212925Boehringer Ingelheim38